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Case Report
Congenital Hypopituitarism due to POU1F1
Gene Mutation
Ni-Chung Lee,1,2 Wen-Yu Tsai,2 Shinn-Forng Peng,3 Yi-Ching Tung,2
Yin-Hsiu Chien,1,2 Wuh-Liang Hwu1,2*
POU1F1 (Pit-1; Gene ID 5449) is an anterior pituitary transcriptional factor, and POU1F1 mutation is
known to cause anterior pituitary hypoplasia, growth hormone and prolactin deficiency, and various de-
gree of hypothyroidism. We report here a patient who presented with growth failure and central hypothy-
roidism since early infancy. However, treatment with thyroxine gave no effect and he subsequently
developed calf muscle pseudohypertrophy (Kocher-Debre-Semelaigne syndrome), elevation of creatinine
kinase, dilated cardiomyopathy, and pericardial effusion. Final diagnosis was made by combined pituitary
function test and sequencing analysis that revealed POU1F1 gene c.698T > C (p.F233S) mutation. The rarity
of the disease can result in delayed diagnosis and treatment.
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Development of the pituitary gland requires a cas-
cade of signaling molecules and transcription fac-
tors. To date, nine major genes that are involved
in hypothalamo-pituitary development have been
recognized, including HESX1, SOX2, SOX3, GLI2,
LHX3, LHX4, TBX19, PROP1, and POU1F1.1
Among these, mutations of PROP1 cause panhy-
popituitarism; POU1F1 mutation causes growth
hormone (GH), prolactin, and thyroid stimulat-
ing hormone (TSH) deficiencies, whereas muta-
tions of other genes cause specific syndromes, for
example, mutation on HESX1 results in septoop-
tic dysplasia.1,2
The POU1F1 gene (Pit-1; Gene ID 5449) is a
tissue-specific transcriptional factor and belongs
to the POU homeodomain family. It regulates GH,
prolactin and TSH β-subunit gene expression,
and somatotroph, lactotroph, and thyrotroph
development of the anterior pituitary gland.1,3
Mutations of POU1F1 account for 7.8% of com-
bined pituitary hormone deficiency (CPHD) and
isolated GH deficiency.4 Clinical manifestations
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of POU1F1 gene mutation include early growth
failure, short stature, various degrees of mental
retardation, characteristic facial features (promi-
nent forehead, marked mid-face hypoplasia, saddle
nose, deep-set eyes, short nose, and anteverted
nostrils), and failure to thrive in infancy.5 The age
of onset in TSH deficiency is variable, whereas
prolactin deficiency does not manifest clinically
in childhood.6 Hypoplastic pituitary gland can
be found by brain magnetic resonance imaging
(MRI), which confirms the role of this transcrip-
tional factor in pituitary development.5 These
patients respond to GH and thyroid hormone re-
placement.7 Since the first report in 1992, about
28 POU1F1 mutations, mostly missense/nonsense
mutations, have been reported in over 60 patients.2
In this article, we report one case of POU1F1
gene mutation that was misdiagnosed as isolated
central hypothyroidism. Treatment with thyroxine
was interrupted due to lack of efficacy, and the
patient developed frank hypothyroidism including
the Kocher-Debre-Semelaigne syndrome, a very
rare disease,8–10 but a correct diagnosis is required
before effective treatment can be instituted.
Case Report
A girl aged 2 years and 2 months, G4P3AA3, was
born after 37 weeks of an uncomplicated preg-
nancy. Both parents were aboriginal Taiwanese,
and their height and mentality were normal. Her
birth weight was 3170 g (75th–90th percentile),
birth length 48 cm (50th percentile), and birth
head circumference 34 cm (75th–90th percentile).
Apgar score was 7 at 1 minute and 9 at 5 min-
utes. Newborn screening for congenital hypothy-
roidism was normal.
Feeding difficulty was noted shortly after birth,
and a heart murmur was found accidentally at the
age of 4 months. At referral, she had severe failure
to thrive (weight 3320 g; < 3rd percentile; height
47.5 cm, < 3rd percentile), developmental delay,
poor oral intake, and hypotonia. Further evalua-
tions revealed normocytic anemia (hemoglobin
6.7 g/dL, mean corpuscular volume 98.9 fL), and
elevations of alanine aminotransferase (54 U/L,
normal: < 41 U/L), aspartate aminotransferase
(91U/L, normal: <37U/L), creatinine kinase (440–
1346 U/L, normal: < 193 U/L), and lactate dehy-
drogenase (259–868 U/L, normal: 230–460 U/L).
She had hypothermia, but normal pulse and res-
piration. Cardiac echo did not show any specific
findings. Renal echo showed bilateral small kid-
neys. The 24-hour urinalysis showed decreased cre-
atinine clearance (26 mL/min/1.73 m2, normal:
40–65 mL/min/1.73 m2). Free thyroxine was
< 0.24 ng/dL (normal: 0.6–1.75 ng/dL), thyroxine
was 0.13 μg/dL (normal: 6.1–14.9 μg/dL), tri-
iodothyronine was 1.99 ng/dL (normal: 75–
260 ng/dL), and TSH was 0.021 μIU/mL (normal:
0.1–0.45 μIU/mL). Brain MRI showed normal
sella turcica, intact pituitary stalk, and sunken di-
aphragma sella (Figure 1, arrow). Sick euthyroid
syndrome was the initial diagnosis. However, 
because of her poor growth, 25 μg/day thyroxine
(7.5 μg/kg/day) was prescribed. Her growth did
not improve, and the medication was stopped at
the age of 1 year 6 months. Karyotype analysis
showed normal female pattern (46,XX).
When we saw her again at the age of 2 years
and 2 months, she had severe, proportional fail-
ure to thrive (weight 5.9 kg, height 59 cm, and
head circumference 41.6 cm, all far below the 3rd
percentile), wide anterior fontanelle (4.5×4.5 cm),
and pale conjunctiva. In addition, she had fine and
Figure 1. T1-weighted image of brain magnetic resonance
imaging. Sagittal view showed normal sella turcica, intact
pituitary stalk, and sunken diaphragma sella (arrow).
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sparse hair, prominent forehead, deep-seated
eyes, saddle nose with anteverted nostrils, poor
tooth growth, bilateral calf muscle pseudohyper-
trophy, and mottling skin (Figure 2). She was alert
but could only make repetitive consonant sounds.
She stood with support and used a spoon for
meals. She grew 11.5 cm in 22 months (growth
rate: 6.2 cm/year). Chest X ray showed cardio-
megaly, and echocardiography demonstrated left
atrial and ventricular dilation, and pericardial ef-
fusion. Her bone age was only 6 months at a
chronological age of 2 years 2 months. Brain MRI
and blood biochemistry revealed similar findings
as the previous studies at 4 months old, except
that her creatine kinase levels was higher
(970–2954 U/L). Her calf muscle hypertrophy
was prominent. Free thyroxine (< 0.24 ng/dL),
TSH (< 0.04 μIU/mL), and GH (< 0.05 ng/mL)
levels were all below the detection limits. A com-
bined anterior pituitary function test was per-
formed. Luteinizing hormone releasing hormone
(100 μg), 100 μg thyrotropin releasing hormone,
and 1 U insulin were given intravenously, and
blood was drawn once every 30 minutes for 
2 hours. The results showed normal cortisol and
gonadotropin responses; however, the responses
for GH, TSH, and prolactin were poor (Table).
Therefore, hypopituitarism was diagnosed.
Mutation analysis of POU1F1 revealed a homo-
zygous c.698T > C (p.F233S) change (Figure 3).
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Figure 2. Facial characteristics of the patient, showing fine
and sparse hair, prominent forehead, deep-seated eyes, sad-
dle nose with anteverted nostrils, and poor tooth growth.
Figure 3. Mutation analysis of POU1F1 revealed a homo-
zygous c.698T > C (p.F233S) change in the patient and
heterozygous on parents (arrows).
Table. Combined anterior pituitary function test by using 100 μg luteinizing hormone releasing hormone,
100 μg thyrotropin releasing hormone, and 1 U insulin
Time Glu GH Cortisol TSH Prolactin FSH LH Estradiol Free T4
(min) (mg/dL) (ng/mL) (μg/dL) (μIU/mL) (ng/mL) (mIU/mL) (mIU/mL) (g/mL) (ng/dL)
0 55 < 0.05 13.3 < 0.15 0.16 3.7 0.15 < 20 < 0.24
30 7 < 0.05 16.2 < 0.15 0.13 15.2 3.92
60 9 < 0.05 23.1 < 0.15 < 0.10 22.1 3.76
90 14 < 0.05 23.9 < 0.15 < 0.10 27.4 3.85
120 16 < 0.05 27.2 < 0.15 0.25 31.3 3.92
Glu = glucose; GH = growth hormone; TSH = thyroid stimulating hormone; FSH = follicle stimulating hormone; LH = luteinizing hormone;
T4 = thyroxine.
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Discussion
In this report, we describe a case of POU1F1-
mutation-induced CPHD with an initial presenta-
tion of retarded growth. Ineffective treatment due
to severe TSH deficiency and poor compliance to
medication led to a full-blown manifestation of
hypothyroidism, including skeletal myopathy,
and cardiomyopathy. Retrospectively, the charac-
teristic facial dysmorphism might have been a
clue for the early diagnosis of this rare disorder.
A high index of suspicion is mandatory for early
diagnosis, as well as replacement therapy with
thyroid hormone and GH to prevent serious
complications in these patients.
POU1F1 has three functional domains: a transac-
tivation domain, a POU-specific, and a POU-
homeo domain. The latter two domains are
DNA-binding homeodomains.3,6,11 POU1F1 mu-
tations and inheritance are heterogeneous.
Mutations in the DNA-binding domains result in
inactivation of POU1F1 protein and autosomal
recessive inheritance. On the other hand, muta-
tions in other regions, inherited as autosomal
dominant, can lead to competitive inhibition of
the mutant/wild-type heterodimer.1,4,12 In general,
recessive mutations are more severe than their
dominant counterparts. Currently, more than 28
POU1F1 mutations have been found in > 60 pa-
tients.2 As far as we are aware, the c.698T > C
(p.F233S) mutation has not been reported before.
Mutation of F233L has been reported in a twin
with CPHD.13 F233 is located at the homeodo-
main of POU1F1 and is a DNA-binding site for
transcription factors that control development and
differentiation.11,13 The location of the amino acid
(F233) is highly conserved and substitution of this
amino acid can result in defects in correct folding,
DNA binding, or other protein interactions.13
Certainly, there is more to be learned of this
disease, such as the etiology of its neurological
manifestations. Careful observation and manage-
ment of more cases will help us to understand
development of the pituitary gland and the brain.
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